Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sadia Khan

Internal Medicine Saginaw, MI Medical Doctor

NPI 1881633048 CMS profile 357442

912 S Washington Ave Ste 2, Saginaw, MI 48601

Open in the dashboard

General payments

$4,068

168 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sadia Khan of Saginaw, MI is reported in the CMS Open Payments database as having received $4,068 across 168 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,055 39
2024 General $879 38
2023 General $750 30
2022 General $426 24
2021 General $382 17
2020 General $113 6
2019 General $463 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sadia Khan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Sadia Khan were reported at $1,055. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Sadia Khan Internal Medicine median Middle half National median
2019 $463 $159 $48–$570 $163
2020 $113 $119 $33–$402 $114
2021 $382 $135 $37–$521 $132
2022 $426 $141 $42–$496 $149
2023 $750 $149 $45–$519 $160
2024 $879 $154 $47–$537 $164
2025 $1,055 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $529 18 payments
  2. Otsuka America Pharmaceutical, Inc. $477 19 payments
  3. Janssen Pharmaceuticals, Inc $322 8 payments
  4. Novo Nordisk Inc $297 15 payments
  5. Axsome Therapeutics, Inc. $279 6 payments
  6. Lilly USA, LLC $206 10 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $175 8 payments
  8. Biogen, Inc. $153 4 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $117 7 payments
  10. Boehringer Ingelheim Pharmaceuticals, Inc. $109 5 payments
  11. Other $1,404 68 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,068 168 payments
Products named General payments · program years 2019–2025
  1. REXULTI $419 15 payments
  2. XARELTO $322 8 payments
  3. Auvelity $279 6 payments
  4. Ozempic $238 12 payments
  5. RYBELSUS $238 12 payments
  6. LOKELMA $198 6 payments
  7. Kerendia $175 8 payments
  8. NUEDEXTA $165 9 payments
  9. GEMTESA $155 8 payments
  10. BREZTRI $138 5 payments
  11. Other $2,247 110 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 109 drugs

Part D claims

4,825

Median for Internal Medicine: 777

Drug cost

$195,667

Median for Internal Medicine: $73,373

Branded share of claims

26.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 181 $59,480
Jardiance Empagliflozin Brand 33 $12,292
Lokelma Sodium Zirconium Cyclosilicate Brand 27 $10,814
Xarelto Rivaroxaban Brand 35 $10,281
Entresto Sacubitril/Valsartan Brand 32 $9,719
Incruse Ellipta Umeclidinium Bromide Brand 21 $8,072
Levothyroxine Sodium Generic 237 $7,974
Lantus Insulin Glargine,hum.Rec.Anlog Brand 79 $6,090
Levemir Insulin Detemir Brand 49 $5,802
Atorvastatin Calcium Generic 354 $3,405

The 10 drugs with the highest cost, of 109 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$57,290

Medicare's payments for the services billed

Medicare patients

395

Average age 75

Services billed

1,114

205 women, 190 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 51%
Chronic kidney disease 50%
Heart failure 48%
Depression 47%
Diabetes 44%
Atrial fibrillation 42%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $76
  • Lundbeck LLC $20
$96 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $89
$89 — —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $86
$86 — —
NUEDEXTA
  • Otsuka America Pharmaceutical, Inc. $51
$51 — —
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $50
$50 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

168 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record